Comparison 4. Benralizumab 10 mg versus placebo.

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
4.1 Rate of moderate or severe exacerbations	1	1130	Rate Ratio (IV, Fixed, 95% CI)	0.91 [0.79, 1.06]
4.1.1 Eosinophils ≧ 220/μL	1	765	Rate Ratio (IV, Fixed, 95% CI)	0.85 [0.71, 1.02]
4.1.2 Eosinophils < 220/μL	1	365	Rate Ratio (IV, Fixed, 95% CI)	1.04 [0.82, 1.32]
4.2 Annual EXACT‐PRO exacerbation rate	1	765	Rate Ratio (IV, Fixed, 95% CI)	0.98 [0.81, 1.19]
4.2.1 Eosinophils ≧ 220/μL	1	765	Rate Ratio (IV, Fixed, 95% CI)	0.98 [0.81, 1.19]
4.3 Rate of severe exacerbations requiring hospitalisation	1	765	Rate Ratio (IV, Fixed, 95% CI)	0.68 [0.49, 0.94]
4.3.1 Eosinophils ≧ 220/μL	1	765	Rate Ratio (IV, Fixed, 95% CI)	0.68 [0.49, 0.94]
4.4 Serious adverse events	1	1129	Odds Ratio (M‐H, Fixed, 95% CI)	0.90 [0.69, 1.17]
4.5 SGRQ total score	1	680	Mean Difference (IV, Fixed, 95% CI)	‐0.87 [‐3.23, 1.49]
4.5.1 Eosinophils ≧ 220/μL	1	680	Mean Difference (IV, Fixed, 95% CI)	‐0.87 [‐3.23, 1.49]
4.6 FEV₁ (L)	1	669	Mean Difference (IV, Fixed, 95% CI)	0.01 [‐0.04, 0.05]
4.6.1 Eosinophils ≧ 220/μL	1	669	Mean Difference (IV, Fixed, 95% CI)	0.01 [‐0.04, 0.05]
4.7 Rescue medication use	1	619	Mean Difference (IV, Fixed, 95% CI)	‐0.59 [‐1.11, ‐0.07]
4.7.1 Eosinophils ≧ 220/μL	1	619	Mean Difference (IV, Fixed, 95% CI)	‐0.59 [‐1.11, ‐0.07]
4.8 Proportion of nights with awakenings	1	638	Mean Difference (IV, Fixed, 95% CI)	‐0.04 [‐0.09, 0.01]
4.8.1 Eosinophils ≧ 220/μL	1	638	Mean Difference (IV, Fixed, 95% CI)	‐0.04 [‐0.09, 0.01]
4.9 COPD Assessment Test (CAT)	1	682	Mean Difference (IV, Fixed, 95% CI)	0.18 [‐0.82, 1.18]
4.9.1 Eosinophils ≧ 220/μL	1	682	Mean Difference (IV, Fixed, 95% CI)	0.18 [‐0.82, 1.18]
4.10 Mortality	1	1129	Odds Ratio (M‐H, Fixed, 95% CI)	0.90 [0.46, 1.76]
4.11 Adverse events	1	1129	Odds Ratio (M‐H, Fixed, 95% CI)	0.96 [0.76, 1.21]